CBX-11 combines Cybrexa’s proprietary alphalex™ tumor targeting technology with an already-approved oral small molecule PARP inhibitor. CBX-11 will be evaluated in combination with DNA damaging chemotherapy for the treatment of patients with solid tumors that lack homologous recombination deficiency (HRD). The company remains on track to submit its Investigational New Drug (IND) application for CBX-11 by the fourth quarter of 2019, with a Phase 1 clinical trial evaluating CBX-11 in combination with chemotherapy anticipated to begin in the first quarter of 2020.  

Details for the poster presentation are as follows:

 Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor
 Permanent Abstract # 2981 / Poster #3
 Session:Diagnostics, Biomarkers, and the Tumor Microenvironment
 Date and Time:Tuesday, April 2; 8:00 am – 12:00 pm EST 
 Location:Georgia World Congress Center, Exhibit Hall B, Poster Section 11
 Presenting Author:...

“This marks the first set of preclinical data supporting our lead candidate CBX-11, which we formally announced at the beginning of the year,” said Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa. “Our alphalex™ tumor targeting technology represents a novel approach to enable the synergistic efficacy of a PARP inhibitor and chemotherapy administered at full dose. We are excited to share these compelling data and take the opportunity to unveil the composition of CBX-11, especially given the current development landscape and high profile of PARP inhibitors.”

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?